In patients with psoriasis or rheumatoid arthritis, the use of tumor necrosis factor inhibitors or hydroxychloroquine, but not methotrexate, was associated with a decrease in the incidence of diabetes compared to other disease-modifying antirheumatic drugs.
In patients with psoriasis or rheumatoid arthritis (RA), the use of tumor necrosis factor (TNF) inhibitors or hydroxychloroquine, but not methotrexate, was associated with a decrease in the incidence of diabetes compared to other disease-modifying antirheumatic drugs (DMARDs).
These were the findings of a new cohort study published in JAMA.
In this observational study, researchers identified a cohort of adult patients diagnosed with either psoriasis or RA within 2 health insurance databases, 1 each in Canada and the United States. Eligible participants must have been diagnosed based on ≥2 visits ≥7 days apart, continuously enrolled in the insurance plan for 12 months prior to the diagnosis, and filled at least 1 prescription for a DMARD after the diagnosis. Participants were stratified into 1 of 4 DMARDs groups (TNF inhibitors, methotrexate, hydroxychloroquine, and other nonbiologic DMARDs). Diagnosis of diabetes was identified with diagnosis codes in combination with a new prescription for a diabetes-specific medication.
In their paper the researchers noted, "Taken in the context of prior research, the current study supports the potential role for systemic immunosupression in prevention and control of diabetes." They further emphasized, "The balance of risks and benefits would likely differ across clinical scenarios. For example in individuals without diabetes or a systemic rheumatic disease, use of a potent immunosuppressive may carry more risk than benefit. However, if an individual also has a systemic rheumatic disease for which a DMARD may be indicated, the ratio may shift toward benefits over risks."
Researchers noted several study limitations in their paper including its observational study design, residual confounding, possible misclassification of diabetes, and lack of differentiating type 1 and type 2 diabetes. However, researchers concluded this study to be hypothesis generating and suggest a randomized controlled trial to test this hypothesis further.
This trial was sponsored by Amgen, manufacturers of 1 of the evaluated TNF inhibitors, etanercept (Enbrel).
SOURCE
Solomon DH, Massarotti E, Garg R, Liu J, Canning C, Schneeweiss S. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA. 2011;305:2525–2531.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.